

INFO-CONNECT

Pain Management in Nursing Home Residents with Dementia

The Facts . . .

- *45 to 80 percent of residents in long-term care facilities report chronic pain.*
- *40 to 60 percent of long-term care residents don't use the 'as-needed' medications prescribed for them.*
- *Untreated pain has serious, varied, and widespread consequences for older adults.*
- *Effective use of behavioral and medication therapies relies on accurate and ongoing assessment of pain.¹*

Assessing Pain in Advanced Dementia¹

- Pain assessment relies on OBSERVING the person's behavior.
- Research suggests that KNOWING the person is key to identifying pain.
- Residents who cannot clearly communicate their discomfort are at high risk for under-treatment of pain.
- All 'traditional' pain assessment scales rely on both verbal and cognitive skills, which make them ineffective in advanced dementia:
 - Responding to 'simple' questions like, "Are you having pain?" may not be possible.
 - Being able to 'point where it hurts' requires problem-solving skills no longer available.
 - Rating the 'intensity' of pain on a scale using numbers or words is beyond the person's ability.

Principles of Pain Management

- Identify and treat multi-dimensional factors that contribute to pain.
 - Depression, anxiety, fatigue, poor eating habits, and nutritional deficits
- Help the resident be comfortable and functional by focusing on overall health and well being.
 - Treatment should decrease pain and improve function, mood, and sleep.

¹ See "INFO-CONNECT: Pain Assessment in Nursing Home Residents with Advanced Dementia," Iowa Geriatric Education Center, for more information on assessment methods.

- Use non-pharmacological interventions in combination with analgesic medication.
 - Using non-pharmacological and analgesic interventions in combination may reduce the level of medication needed.
 - Below is a table of non-pharmacological interventions that may be recommended for those with advanced dementia.

| NON-PHARMACOLOGICAL INTERVENTIONS | |
|------------------------------------|--|
| Comfort Measures: | Distraction/Redirection: |
| Positioning | Art therapy |
| Verbal reassurance | Music therapy |
| Gentle touch | Pet therapy |
| Massage | Humor/laughter |
| Support/Counseling: | Relaxation techniques |
| Spiritual support | Activities/recreation |
| Support groups | Life review/reminiscence |
| Talking with friends | |
| Social support | Cognitive Techniques: |
| Stress control | Psychotherapy |
| | Biofeedback |
| | Guided imagery/meditation |
| | Hypnosis |
| Supportive Physical Methods | Alternative Therapies: |
| Balance and fall protection | Physical therapy |
| Heat/cold applications | Ultrasound |
| Hydrotherapy | Chiropractic |
| Bracing/splinting | Acupuncture |
| Joint protection | Transcutaneous Electrical Nervous Stimulation (TENS) |
| Stretching exercises | |
| Movement and range of motion | |

- The World Health Organization (WHO) suggests using a three-step ladder for pharmacological management of pain.
 1. Start with nonopioids
 2. Proceed to opioid therapies
 3. Use adjunctive nonopioid medications to augment opioid medication

- Follow basic principles to ensure safe and effective analgesic use.
 - Use the least invasive route of administration.
 - Use short-acting drugs for episodic pain and around-the-clock administration for continuous pain.
 - Use long-acting or sustained release formulas for continuous pain only.
 - Adjust doses carefully following the motto: "Start low and go (titrate) slow".
 - Use both short-acting and long-acting opioids for chronic pain.
 - Consider alternatives for neuropathic pain.
 - Topical analgesics may be helpful with arthritic pain.
- Recognize that older adults, as a group, are more sensitive to analgesics and individual side effects may vary considerably.
Anticipate, monitor, and treat the side effects prophylactically.
 - Anticipate mild cognitive impairment and sedation until tolerance develops.
 - Start a bowel protocol.
- Avoid certain analgesic drugs altogether when treating residents.
 - Meperidine
 - Methadone
 - Propoxyphene



CARES Model²

This conceptual model helps health care facilities with incorporating national pain standards and guidelines into practice.

Commitment - identify facility commitment toward excellent pain management

Assessment - develop pain assessment criteria and documentation for specific patient populations

Responsibility - assign responsibility within the facility to ensure that standards are continually reviewed and maintained

Education - develop ongoing health professional competency guidelines, educational programs, and an organized system for patient and family education

Standards - develop patient care standards defining expected outcomes of care

² Weissman DE. (1995). Educating home health professionals in cancer pain management. *Home Health Care Consultant*, 2,10-18. Used with permission.

For more information about the CARES model, please contact Sandra Muchka, RN, OCN, by phone at (414) 805-6828 or email at smuchka@mcw.edu

NON-OPIOID MEDICATIONS³

| Drug | Dose | Max Dose/24 | Medication-related Adverse Effects | Comments |
|--|---|--------------------|---|--|
| Acetaminophen (Tylenol®) | 325-1000 mg every 4-6 hrs | 4000 mg | Hepatotoxicity above maximum dose. | Avoid exceeding maximum dose. Potent analgesic but no anti-inflammatory effect. No GI or antiplatelet side effects. Potentiates nonsteroidal anti-inflammatory drugs and opiates. Those consuming more than 2 ounces of alcohol per day should not exceed 2000 mg Acetaminophen per day due to increased risk of liver toxicity. |
| Nonselective Non-steroidal anti-inflammatory Ibuprofen, Naproxen, others COX-2 selective inhibitor Celecoxib (Celebrex®) | Individualize dosage 100-200 mg QD or BID 200mg | | Serious gastrointestinal toxicity can occur. May cause an increased risk of serious cardiovascular events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. | May be considered rarely, with extreme caution when other therapies fail. Use requires ongoing assessment of adverse events/risks/benefits. Contraindicated in individuals with active peptic ulcer disease, chronic kidney disease or heart failure. Relatively contraindicated in individuals with hypertension, <i>H. pylori</i> , history of peptic ulcer or concomitant use of corticosteroids or SSRIs. Use as a proton pump inhibitor for gastrointestinal protection with nonselective NSAIDs. Use as a proton pump inhibitor for gastrointestinal protection in individuals on celecoxib and aspirin. |
| | | | | |

Adapted from:

³ American Geriatrics Society (AGS) Panel on Chronic Pain in Older Adults. *Journal of the American Geriatrics Society*. 2002;50(suppl):520-524. Used with permission.

OPIOID MEDICATIONS⁴

| Drug | Dose | Max Dose/24 | Medication-related Adverse Effects | Comments |
|--|---|--------------------|--|---|
| Tramadol (Ultram®) | 25 mg every 4-6 hrs | 300 mg | Side effects include dizziness/vertigo, nausea, constipation. | Central analgesic with weak opioid activity used for moderate to severe pain in osteoarthritis and other chronic pain syndromes. Bowel regimen mandatory. |
| Hydrocodone (Vicoden®, Lortab®) | 5-10 mg every 3-4 hrs | NA | Acetaminophen, nonsteroidal anti-inflammatory drug combinations limit dose; toxicity similar to morphine. Constipation. | Do not exceed recommended maximum dose of acetaminophen. Begin a bowel program early. |
| Morphine, Immediate release (Roxanol®) | 2.5-30 mg every 4-6 hrs. | NA | Intermediate half-life. Older adults more sensitive to side effects. Constipation. | Continuous use for continuous pain; intermittent use for episodic pain. Titrate doses with short acting then convert to sustained release. Gold standard for pain relief. Tolerance develops for all side effects except constipation. Bowel regimen mandatory. |
| Morphine, Sustained release (MS Contin®, Oramorph SR®, SR®) | 15-30 mg every 12 hrs. If previously on IR divide 24 hr used and administer q12 hrs | NA | Rarely requires more frequent dosing. Constipation. | Escalate dose slowly due to drug accumulation; immediate release opioid often needed for breakthrough pain. Switch from IR to sustained release at same dose. Dosing interval can be adjusted if pain is not controlled. Do not crush pills. Bowel regimen mandatory. |
| Oxycodone, immediate release (IR) (Percodan®, Percocet®, Tylox®) | 5-10 mg every 4-6 hrs | NA | Oxycodone is available as a single agent. Acetaminophen-nonsteroidal anti-inflammatory drug combinations limit dose; toxicity similar to morphine. Constipation. | Do not exceed recommended maximum dose of acetaminophen or aspirin. Begin bowel program early. |
| Oxycodone, Sustained release (OxyContin®) | 10-20 mg every 12hrs. If previously on IR divide 24 hr use and administer q12 hrs | NA | Same as sustained-release morphine. Constipation. | Immediate-release opioid often needed for break-through pain. Bowel regimen mandatory. |
| Hydromorphone (Dilaudid®) | 2 mg oral every 3-4 hrs | NA | Half-life may be shorter than morphine (3 hrs); toxicity similar. Constipation. | Similar to morphine; start low and titrate to comfort; give continuously (every 3-4 hrs) for continuous chronic pain. Bowel regimen mandatory. |
| Fentanyl, transdermal (Duragesic®) | NA>25 mcg/h not recommended for opioid naive patients | NA | Effective activity may exceed 72 hrs in older patient (designed for 3-day duration). Constipation. | Titrate slowly using immediate-release analgesics for break-through pain; peak effects of first dose may take 18-24 hrs. Caution: Fever increases dose absorption rate. Expensive, use selectively. Bowel regimen mandatory. |

Adapted from:

⁴ American Geriatrics Society (AGS) Panel on Chronic Pain in Older Adults. *Journal of the American Geriatrics Society*. 2002;50(suppl):520-524. Used with permission.

ADJUVANT MEDICATIONS⁵

| Drug | Starting Dose | Max Dose/24 | Indication | Medication-related Adverse Effects | Comments |
|---|--|-------------|---|--|--|
| Corticosteroids | | | | | |
| Prednisone | 2.5-5.0 mg daily | NA | Inflammatory disease | Increased risk of hyperglycemia, osteopenia, and Cushing's. | Avoid high dose for long-term use. |
| Tricyclic Antidepressants | | | | | |
| Desipramine Nortriptyline | 10 mg at bedtime | 25-100 mg | Neuropathic pain, sleep disturbance | Increased sensitivity to side effects, especially anticholinergic effects. | Monitor carefully for anticholinergic effects, Desipramine may be as effective as amitriptyline with fewer side effects; start at lowest dose possible; titrate bedtime dose 10 mg q 3-5 days. |
| Anticonvulsants | | | | | |
| Carbamazepine (Tegretol®) | 100 mg | 2500 mg | Lancinating pain (e.g., trigeminal neuralgia) | Can cause somnolence, ataxia, dizziness, leukopenia, thromocytopenia, and rarely aplastic anemia. | Start at 100 mg daily; increase slowly; check liver function tests, complete blood count (CBC), renal function at baseline; CBC at 2 and 8 wks. |
| Gabapentin (Neurontin®) | 100 mg | 3600 mg | Neuropathic pain | May prove to have less serious side-effects than carbamazepine. | Neuropathic doses not established; monitor for idiosyncratic side effects (e.g., ankle swelling, ataxia). |
| Topical Agents | | | | | |
| Capsaicin (Zostrix® cream, lotion) | 0.025% topically every 6 hrs | NA | Apply to the site of pain. | Initial burning sensation. | Useful for neuropathic pain. Solarcaine® may help reduce initial burning sensation. Patients should be warned about the transient burning sensation that follows application and need for regular use to maintain effectiveness. Skipping doses results in reaccumulation of substance P and return of pain. |
| Capsaicin (Zostrix-HP®) | 0.075% topically every 6 hrs | | | | As with 0.025% creams and lotions. Several weeks may be needed to be effective. Clinical trials are lacking. |
| Counter irritants containing menthol (Ben-Gay®, Icy Hot®) | Topically | NA | Apply to the site of pain. | May cause local irritation, especially in patients with sensitive skin. | May be effective in self-management of osteoarthritis. |
| Lidocaine Patch 5% (Lidoderm®) | Up to three patches to intact skin in painful area | | Apply once for 12 hours within a 24 hr period | Localized neuropathic pain | Application site reactions Little systemic absorption |
| Didofenac 1% Gel (Voltaren® Gel) | 4 gm to affected lower extremity joint or 2 gm to affected upper extremity joint QID | 32 grams | Pain of osteoarthritis of knees and hands | Application site reactions Carries same warning as oral nonselective non-steroidal anti-inflammatory drugs | Should be used with the same caution as orally administered NSAIDS |

Adapted from:

⁵ American Geriatric Society (AGS) Panel on Chronic Pain in Older Adults. *Journal of the American Geriatric Society*. 2002;50(suppl):52-65-24. Used with permission.
by Michael Kelly, PharmD, MS.

A Service of the:

Iowa Geriatric Education Center
University of Iowa
2153 Westlawn
Iowa City, IA 52242
(319) 353-5756
<http://www.healthcare.uiowa.edu/igec>

Funded by
The Department of Health Resources and Services Administration (HRSA)

Content provided by:

Marianne Smith, PhD, ARNP, BC
Assistant Professor
University of Iowa College of Nursing

Michael Kelly, PharmD, MS
Associate Professor (Clinical)
College of Pharmacy
and Department of Family Medicine
Roy J. and Lucille A. Carver College of Medicine

Editorial review by:

Margo Schilling, MD
Associate Professor of Clinical Medicine
Division of General Internal Medicine
University of Iowa